Clinical Pharmacology

Selected news for the healthcare topic - Clinical Pharmacology, collected since 10/2017. This healthcare topic shares news with Food and Drug Administration, Heart Disease, Pfizer, COVID-19, Clinical Research and over a hundred others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/19/2022 Tuzistra XR (Codeine Polistirex, Chlorpheniramine Polistirex Extended-release Oral Suspension) - updated on RxList rxlist.com ... PRECAUTIONS ]. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels [see CLINICAL PHARMACOLOGY ], resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to codeine.Avoid the use of TUZISTRA XR while taking a CYP3A4 inhibitor. If concomitant use is necessary ...
1/17/2022 2022 Virtual Poster Symposium Call for Abstracts accp.com ... and travel restrictions, an alternative means for individuals to present their research and scholarship to peers and to engage in dialogue with colleagues is needed more than ever.All investigators in clinical pharmacy and clinical pharmacology , ACCP members and nonmembers alike, are invited to submit abstracts. The fee to submit an abstract is $50.The deadline to submit abstracts (EXCLUDING Research-in-Progress abstracts) is March 28, 2022. The deadline ...
1/11/2022 Quviviq (Daridorexant Tablets) - new on RxList rxlist.com ... Clinically Important Interactions With QUVIVIQ Table 2 : Clinically Important Drug Interactions with QUVIVIQ Strong or Moderate CYP3A4 Inhibitors Clinical Implications: Concomitant use with a strong or moderate CYP3A4 inhibitor increases exposure to daridorexant [see CLINICAL PHARMACOLOGY ], which may increase the risk of QUVIVIQ adverse reactions. Prevention or Management: The recommended dose of QUVIVIQ is 25 mg when used with a moderate CYP3A4 inhibitor [see DOSAGE AND ADMINISTRATION ]. Concomitant use of ...
1/11/2022 Assessing And Treating Clients With Impulsivity, Compulsivity, And Addiction essayswritershub.com ... adulthood, study finds. Retrieved from https://www.sciencedaily.com/releases/2016/01/160120201324.htm Note: Retrieved from Walden Library databases. Grant, J. E., Odlaug, B. L., & Schreiber, L. N. (2014). Pharmacological treatments in pathological gambling. British Journal of Clinical Pharmacology , 77(2), 375–381. doi:10.1111/j.1365-2125.2012.04457.x Note: Retrieved from Walden Library databases. Loreck, D., Brandt, N. J., & DiPaula, B. (2016). Managing opioid abuse in older adults: Clinical considerations and challenges. Journal ...
1/11/2022 ACCP Policy Statements: "Off-Label Use of Ketamine: A Challenging Drug Treatment Delivery Model with an Inherently Unfavorable Risk-Benefit Profile" & "Pharmacological Arguments Against the Use of Ketamine in Non-Medical Settings" PR Newswire ASHBURN,Va., Jan. 11, Two policy statements from the American College of Clinical Pharmacology ® (ACCP) have recently been published on the topic of ketamine use in off-label or non-medical settings. Ketamine is a dissociative anesthetic agent that is FDA-approved for use by or under the direction of physicians experienced in the administration of general anesthetics." Off–Label Use of Ketamine: A Challenging Drug Treatment Delivery Model ...
1/11/2022 Developers Advised to Challenge Regulatory Standards to Speed Development of Biosimilars centerforbiosimilars.com Developers can bring biosimilars to market more quickly and at lower cost by challenging regulatory requirements and restricting testing of these agents to analytical similarity and clinical pharmacology , Sarfaraz K. Niazi, PhD, writes in a December 2021 paper in the journal Expert Opinion on Biological Therapy.\n\nNiazi is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, founder of the biosimilars companies ...
1/11/2022 CenExel Clinical Research Acquires Rocky Mountain Movement Globe Newswire ... The CenExel Centers of Excellence network now comprises 13 of the most proficient clinical research sites in the country, with special emphases on Neurology, Pain, Psychiatry, Vaccines/Immunology, Dermatology, Ethnic-bridging, Sleep studies, and Clinical Pharmacology . Each of the CenExel research units has outstanding records of assisting pharmaceutical sponsors with protocol development, study design, and conducting Phase I-IV trials to develop new therapeutics for improved patient care.CenExel RMCR ...
1/11/2022 CenExel Clinical Research Acquires Rocky Mountain Movement Disorders Center bakersfield.com ... The CenExel Centers of Excellence network now comprises 13 of the most proficient clinical research sites in the country, with special emphases on Neurology, Pain, Psychiatry, Vaccines/Immunology, Dermatology, Ethnic-bridging, Sleep studies, and Clinical Pharmacology . Each of the CenExel research units has outstanding records of assisting pharmaceutical sponsors with protocol development, study design, and conducting Phase I-IV trials to develop new therapeutics for improved patient care.CenExel RMCR ...
1/10/2022 Duetact (Pioglitazone Hydrochloride and Glimepiride Tablets) - updated on RxList rxlist.com ... CYP2C8 inhibitors should switch to individual components of DUETACT, unless the prescribing health care provider determines that the benefit of DUETACT clearly outweighs the risk of increased pioglitazone exposure [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ]. CYP2C8 Inducers PioglitazoneAn inducer of CYP2C8 (e.g., rifampin ) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with pioglitazone, changes in diabetes ...
1/10/2022 CenExel Clinical Research Acquires California Neuroscience Globe Newswire ... The CenExel Centers of Excellence network now comprises 13 of the most proficient clinical research sites in the country, with special emphases on Neurology, Pain, Psychiatry, Vaccines/Immunology, Dermatology, Ethnic-bridging, Sleep studies, and Clinical Pharmacology . Each of the CenExel research units has outstanding records of assisting pharmaceutical sponsors with protocol development, study design, and conducting Phase I-IV trials to develop new therapeutics for improved patient care.CenExel CNR ...
1/10/2022 CenExel Clinical Research Acquires California Neuroscience Research bakersfield.com ... The CenExel Centers of Excellence network now comprises 13 of the most proficient clinical research sites in the country, with special emphases on Neurology, Pain, Psychiatry, Vaccines/Immunology, Dermatology, Ethnic-bridging, Sleep studies, and Clinical Pharmacology . Each of the CenExel research units has outstanding records of assisting pharmaceutical sponsors with protocol development, study design, and conducting Phase I-IV trials to develop new therapeutics for improved patient care.CenExel CNR ...
1/6/2022 HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology Yahoo News ... 06, 2022 --( BUSINESS WIRE )--HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology. Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development. Most recently Dr. Chen served as Clinical Development Director at Novartis where she contributed to the development of therapeutics for cardio ...
1/6/2022 HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology | Business Wire Business Wire ... ROCKVILLE, Md.--( BUSINESS WIRE )--HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology. Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development. Most recently Dr. Chen served as Clinical Development Director at Novartis where she contributed to the development of therapeutics for cardio ...
1/6/2022 HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology singaporenewslive.com ... Md.–(BUSINESS WIRE)–HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology. Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development. Most recently Dr. Chen served as Clinical Development Director at Novartis where she contributed to the development of therapeutics for cardio ...
1/6/2022 HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology intellasia.net HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology]SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology. Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development. Most recently Dr. Chen served as Clinical ...
1/6/2022 Health Sciences: Assistant/Associate Professor academickeys.com Health SciencesAssistant/Associate ProfessorUniversity of South AlabamaUniversity of South Alabama Title Assistant/Associate Professor University Department Application Deadline Open until filled [University of South Alabama]Mobile, AL, United States[Physician Assistant Studies]- Assistant ProfessorAssociate Professor- Physician AssistantPharmaceutical SciencesHealth Sciences - GeneralThe Pat Capps Covey College of Allied Health Professions at the University of South Alabama invitesapplications for the position of full-time faculty ...
1/6/2022 Health Sciences: Assistant/Associate Professor academickeys.com ... Associate Professor, candidates must provide evidence of an established research agenda (e.g., peer-reviewed publications, grant funding, etc.) that meets department and college standards for that rank. We seek candidates with content knowledge in clinical pharmacology and therapeutics, physiology, and pathophysiology. A preferred candidate would have experience in teaching pharmacology with clinical implications to include drug metabolism and a minimum of 3 years of clinical or teaching experience.Specific responsibilities ...
1/5/2022 Amturnide (Aliskiren, Amlodipine and Hydrochlorothiazide Tablets) - updated on RxList rxlist.com ... and amlodipine, amlodipine and HCTZ, and aliskiren and HCTZ. Studies with the individual aliskiren, amlodipine, and HCTZ components are described below. AliskirenCyclosporine : Avoid coadministration of cyclosporine with aliskiren [see WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY ].Itraconazole : Avoid coadministration of itraconazole with aliskiren [see WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY ].Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors) : In patients who are elderly, volume-depleted ...
1/5/2022 Tarpeyo (Budesonide Delayed Release Capsules) - new on RxList rxlist.com ... to placebo were consistent with hypercortisolism. DRUG INTERACTIONS Interaction With CYP3A4 InhibitorsBudesonide is a substrate for CYP3A4. Avoid use with potent CYP3A4 inhibitors; e.g. ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine [see CLINICAL PHARMACOLOGY ].Avoid ingestion of grapefruit juice with TARPEYO. Intake of grapefruit juice, which inhibits CYP3A4 activity, can increase the systemic exposure to budesonide [see CLINICAL PHARMACOLOGY ]. Warnings & PrecautionsIncluded as part of the "PRECAUTIONS" Section ...
1/4/2022 Entadfi (Finasteride and Tadalafil Capsules) - new on RxList rxlist.com ... different indication and BPH included: gastroesophageal reflux disease, upper abdominal pain, nausea, vomiting, arthralgia, and muscle spasm. Back PainBack pain or myalgia was reported at incidence rates described in Table 3. In tadalafil clinical pharmacology trials, back pain or myalgia generally occurred 12 to 24 hours after dosing and typically resolved within 48 hours. The back pain/myalgia associated with tadalafil treatment was characterized by diffuse bilateral lower lumbar ...